These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29881461)

  • 21. An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations.
    Mullen J; Cockell SJ; Woollard P; Wipat A
    PLoS One; 2016; 11(5):e0155811. PubMed ID: 27196054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The assessment of efficient representation of drug features using deep learning for drug repositioning.
    Moridi M; Ghadirinia M; Sharifi-Zarchi A; Zare-Mirakabad F
    BMC Bioinformatics; 2019 Nov; 20(1):577. PubMed ID: 31726977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug repositioning using drug-disease vectors based on an integrated network.
    Lee T; Yoon Y
    BMC Bioinformatics; 2018 Nov; 19(1):446. PubMed ID: 30463505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inferring new drug indications using the complementarity between clinical disease signatures and drug effects.
    Jang D; Lee S; Lee J; Kim K; Lee D
    J Biomed Inform; 2016 Feb; 59():248-57. PubMed ID: 26707452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional data: a new gateway to drug repositioning?
    Iorio F; Rittman T; Ge H; Menden M; Saez-Rodriguez J
    Drug Discov Today; 2013 Apr; 18(7-8):350-7. PubMed ID: 22897878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
    Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
    PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
    Cheng F; Hong H; Yang S; Wei Y
    Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network.
    Jadamba E; Shin M
    Biomed Res Int; 2016; 2016():7147039. PubMed ID: 28127549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repositioning for rare diseases: Knowledge-based success stories.
    Scherman D; Fetro C
    Therapie; 2020 Apr; 75(2):161-167. PubMed ID: 32164975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering.
    Wang F; Ding Y; Lei X; Liao B; Wu FX
    IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(2):953-965. PubMed ID: 32845842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico prediction of novel therapeutic targets using gene-disease association data.
    Ferrero E; Dunham I; Sanseau P
    J Transl Med; 2017 Aug; 15(1):182. PubMed ID: 28851378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in drug repositioning for the discovery of new anticancer drugs.
    Shim JS; Liu JO
    Int J Biol Sci; 2014; 10(7):654-63. PubMed ID: 25013375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel therapeutics for complex diseases from genome-wide association data.
    Grover MP; Ballouz S; Mohanasundaram KA; George RA; Sherman CD; Crowley TM; Wouters MA
    BMC Med Genomics; 2014; 7 Suppl 1(Suppl 1):S8. PubMed ID: 25077696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug repurposing: Iron in the fire for older drugs.
    Sonaye HV; Sheikh RY; Doifode CA
    Biomed Pharmacother; 2021 Sep; 141():111638. PubMed ID: 34153846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From drug repositioning to target repositioning: prediction of therapeutic targets using genetically perturbed transcriptomic signatures.
    Namba S; Iwata M; Yamanishi Y
    Bioinformatics; 2022 Jun; 38(Suppl 1):i68-i76. PubMed ID: 35758779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.
    Le BL; Andreoletti G; Oskotsky T; Vallejo-Gracia A; Rosales R; Yu K; Kosti I; Leon KE; Bunis DG; Li C; Kumar GR; White KM; García-Sastre A; Ott M; Sirota M
    Res Sq; 2021 Mar; ():. PubMed ID: 33821262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on Drug Repurposing: Re-written saga of the drug's fate.
    Gns HS; Gr S; Murahari M; Krishnamurthy M
    Biomed Pharmacother; 2019 Feb; 110():700-716. PubMed ID: 30553197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating GWAS Findings to Inform Drug Repositioning Strategies for COVID-19 Treatment.
    Tsai MJ; Jeong S; Yu F; Chen TF; Li PH; Juan HF; Huang JH; Hsu YH
    Res Sq; 2023 Oct; ():. PubMed ID: 37886583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis.
    Toro-Domínguez D; Carmona-Sáez P; Alarcón-Riquelme ME
    Arthritis Res Ther; 2017 Mar; 19(1):54. PubMed ID: 28284231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug repositioning: a brief overview.
    Jourdan JP; Bureau R; Rochais C; Dallemagne P
    J Pharm Pharmacol; 2020 Sep; 72(9):1145-1151. PubMed ID: 32301512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.